NASDAQ: KAKineta Inc Stock
$0.53+0.04 (+8.16%)
Updated Apr 19, 2024
KA Price
$0.53
Fair Value Price
N/A
Market Cap
$5.78M
52 Week Low
$0.33
52 Week High
$5.39
P/E
-0.41x
P/B
2x
P/S
7.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.44M
Earnings
-$14.10M
Gross Margin
100%
Operating Margin
-252.88%
Profit Margin
-259.1%
Debt to Equity
2.5
Operating Cash Flow
-$16M
Beta
0.84
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
KA Overview
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KA is good value based on its book value relative to its share price (2x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
KA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more KA due diligence checks available for Premium users.
Be the first to know about important KA news, forecast changes, insider trades & much more!
KA News
Valuation
KA fair value
Fair Value of KA stock based on Discounted Cash Flow (DCF)
Price
$0.53
Fair Value
$1.81
Undervalued by
70.64%
KA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
15.81x
Market
40.51x
KA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2x
Industry
5.74x
KA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KA's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.7M
Profit Margin
0%
KA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.3M
Liabilities
$7.2M
Debt to equity
2.5
KA's short-term liabilities ($7.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KA's short-term assets ($5.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
$0.0
Financing
$2.2M
KA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KA vs Biotech Stocks
Kineta Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.